{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:27Z","timestamp":1791312087631,"version":"4.3.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the diagnostic value of combining prostate health index (PHI) and soluble epithelial cadherin (sE-cadherin) in prostate cancer (PCa) detection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included 250 benign prostatic hyperplasia (BPH) and 250 PCa patients (2020\u20132024). PCa patients were categorized by disease stage (I-II:115; III-IV:135), bone metastasis (non-metastatic:171; metastatic:79), and Gleason score (\u22648:136; &amp;gt;8:114). Serum sE-cadherin (ELISA), tPSA, fPSA, and p2PSA (chemiluminescence) were measured; PHI was calculated. ROC curves evaluated diagnostic performance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>sE-cadherin, tPSA, p2PSA, and PHI levels were significantly higher in PCa vs. BPH (P&amp;lt;0.05), with further elevations in advanced stages, metastatic cases, and Gleason &amp;gt;8 (P&amp;lt;0.05). ROC analysis demonstrated AUCs of 0.719 (sE-cadherin), 0.761 (PHI), and 0.792 (combined), indicating superior diagnostic accuracy for the combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combining sE-cadherin and PHI enhances PCa detection accuracy, correlating with disease severity, metastasis, and aggressiveness.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1531866","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:37:45Z","timestamp":1759210665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The diagnostic value of prostate health index combined with soluble e-cadherin for prostate cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yeasin","family":"Ahamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marofe","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantanu","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on prostate cancer epidemiology and risk factors-A systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF02796203","article-title":"Prostate cancer: a comprehensive review","volume":"17","author":"Pentyala","year":"2000","journal-title":"Med Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2024.03.011","article-title":"Prostate cancer radioligand therapy: beta-labeled radiopharmaceuticals","volume":"19","author":"Yechiel","year":"2024","journal-title":"PET Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020178","article-title":"Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis","volume":"30","author":"Berenguer","year":"2023","journal-title":"Curr Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e48252","DOI":"10.7759\/cureus.48252","article-title":"An in-depth look into the epidemiological and etiological aspects of prostate cancer: A literature review","volume":"15","author":"Al-Ghazawi","year":"2023","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145036","article-title":"Hereditary predisposition to prostate cancer: from genetics to clinical implications","volume":"21","author":"Brandao","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102925","article-title":"The impact of lifestyle on prostate cancer: A road to the discovery of new biomarkers","volume":"11","author":"Leitao","year":"2022","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_82_24","article-title":"Metastatic onset of prostate carcinoma: A clinical and pathological challenge","author":"Dema","year":"2024","journal-title":"Indian J Pathol Microbiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acssensors.3c01402","article-title":"Point-of-care prostate specific antigen testing: examining translational progress toward clinical implementation","volume":"8","author":"Garg","year":"2023","journal-title":"ACS Sens"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00604-017-2410-1","article-title":"Nanomaterial-based biosensors for detection of prostate specific antigen","volume":"184","author":"Damborska","year":"2017","journal-title":"Mikrochim Acta"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1420190","article-title":"Next-generation sequencing impact on cancer care: applications, challenges, and future directions","volume":"15","author":"Zalis","year":"2024","journal-title":"Front Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101542","DOI":"10.1016\/j.tranon.2022.101542","article-title":"An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs","volume":"26","author":"Bilal","year":"2022","journal-title":"Transl Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030082","article-title":"Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications","volume":"6","author":"Testa","year":"2019","journal-title":"Medicines (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.63300","article-title":"The role of N-cadherin\/c-Jun\/NDRG1 axis in the progression of prostate cancer","volume":"17","author":"Quan","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030445","article-title":"Prostate cancer epigenetics: from basic mechanisms to clinical implications","volume":"9","author":"Yegnasubramanian","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2023.0089","article-title":"RNA-sequencing analysis indicates that N-cadherin promotes prostate cancer progression by the epigenetic modification of key genes","volume":"42","author":"Quan","year":"2023","journal-title":"DNA Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/1871530320666200719020709","article-title":"Prostate carcinogenesis: insights in relation to epigenetics and inflammation","volume":"21","author":"Pandareesh","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1918167117","article-title":"The functional activity of E-cadherin controls tumor cell metastasis at multiple steps","volume":"117","author":"Na","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1151879","article-title":"Prognostic impact of the loss of E-cadherin and de novo expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma","volume":"13","author":"Hakim","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020239","article-title":"Overexpression of E-cadherin is a favorable prognostic biomarker in oral squamous cell carcinoma: A systematic review and meta-analysis","volume":"12","author":"Lorenzo-Pouso","year":"2023","journal-title":"Biol (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207624","article-title":"Role of cadherins in cancer-A review","volume":"21","author":"Kaszak","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13674","DOI":"10.1111\/aji.13674","article-title":"Soluble E-cadherin: A marker of genital epithelial disruption","volume":"89","author":"Liu","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16457","article-title":"A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort","volume":"135","author":"Chiu","year":"2025","journal-title":"BJU Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.865436","article-title":"Mechanisms of cell adhesion molecules in endocrine-related cancers: A concise outlook","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e969112","DOI":"10.4161\/21688362.2014.969112","article-title":"Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis","volume":"2","author":"Liu","year":"2014","journal-title":"Tissue Barriers"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101118","article-title":"The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges","volume":"8","author":"Loh","year":"2019","journal-title":"Cells"},{"key":"B30","article-title":"Correlation between E-cadherin expression and tumor grade, proliferation, microvascular density, and apoptosis in canine cutaneous squamous cell carcinoma","volume":"87","author":"Gupta","year":"2023","journal-title":"Can J Vet Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/10408363.2022.2033161","article-title":"Prostate cancer biomarkers: a practical review based on different clinical scenarios","volume":"59","author":"Falagario","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B32","article-title":"Modern biomarkers in prostate cancer diagnosis","volume":"73","author":"Porzycki","year":"2020","journal-title":"Cent Eur J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.10.017","article-title":"Molecular biomarkers for the detection of clinically significant prostate cancer: A systematic review and meta-analysis","volume":"46","author":"Del Pino-Sedeno","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17562872221103988","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","volume":"14","author":"Farha","year":"2022","journal-title":"Ther Adv Urol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"159 e17","DOI":"10.1016\/j.urolonc.2024.02.009","article-title":"Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study","volume":"42","author":"Zhu","year":"2024","journal-title":"Urol Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13046-015-0161-6","article-title":"sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients","volume":"34","author":"Tsaur","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/biology10101007","article-title":"Deciphering the molecular machinery-influence of sE-cadherin on tumorigenic traits of prostate cancer cells","volume":"10","author":"Tsaur","year":"2021","journal-title":"Biol (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"104232","DOI":"10.1016\/j.critrevonc.2023.104232","article-title":"Molecular biomarkers in prostate cancer tumorigenesis and clinical relevance","volume":"194","author":"Alqualo","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4111\/icu.20200395","article-title":"Clinical utility of current biomarkers for prostate cancer detection","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40364-021-00299-4","article-title":"E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors","volume":"9","author":"Burandt","year":"2021","journal-title":"biomark Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02598","article-title":"The E-cadherin cleavage associated to pathogenic bacteria infections can favor bacterial invasion and transmigration, dysregulation of the immune response and cancer induction in humans","volume":"10","author":"Devaux","year":"2019","journal-title":"Front Microbiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"408047","DOI":"10.1155\/2014\/408047","article-title":"Levels of soluble E-cadherin in breast, gastric, and colorectal cancers","volume":"2014","author":"Repetto","year":"2014","journal-title":"BioMed Res Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.689139","article-title":"Overview on the role of E-cadherin in gastric cancer: dysregulation and clinical implications","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B44","article-title":"Evaluation of E-cadherin expression in gastric cancer and its correlation with clinicopathologic parameters","volume":"11","author":"Torabizadeh","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cjp2.61","article-title":"T-cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistance","volume":"3","author":"Dasen","year":"2017","journal-title":"J Pathol Clin Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041184","article-title":"Beyond PSA: the role of prostate health index (phi)","volume":"21","author":"Ferro","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2020.04.004","article-title":"Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4\u201310 ng\/mL","volume":"27","author":"Nassir","year":"2020","journal-title":"Saudi J Biol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235932","article-title":"The role and significance of bioumoral markers in prostate cancer","volume":"13","author":"Constantin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.11.08","article-title":"Friend or foe: role of E-cadherin in prostate cancer metastasis","volume":"5","author":"Lin","year":"2016","journal-title":"Transl Androl Urol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2005420","DOI":"10.1080\/21688370.2021.2005420","article-title":"Dual role of E-cadherin in cancer cells","volume":"10","author":"Rubtsova","year":"2022","journal-title":"Tissue Barriers"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.07.020","article-title":"P120 and E-cadherin: Double-edged swords in tumor metastasis","volume":"60","author":"Venhuizen","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.563","article-title":"Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K\/Akt\/mTOR signaling","volume":"33","author":"Brouxhon","year":"2014","journal-title":"Oncogene"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"B55","first-page":"9","article-title":"Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment","volume":"69","author":"Bjurlin","year":"2016","journal-title":"Cent Eur J Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1523849","article-title":"Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing","volume":"20","author":"Ikeda","year":"2019","journal-title":"Cancer Biol Ther"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1531866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:37:46Z","timestamp":1759210666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1531866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":56,"alternative-id":["10.3389\/fendo.2025.1531866"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1531866","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"1531866"}}